CTRI/2023/02/050006
Not yet recruiting
未知
A descriptive study to assess the impact of post COVID conditions on quality of life among employees of selected institutes of MAHE, Manipal, Udupi district.
Anamika Das0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Anamika Das
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.The study will be delimited to only those who tested positive for COVID19 infection
- •2\.The study will be delimited to employees of selected institutions of MAHE, Manipal.
- •3\.The study will be delimited to only those who voluntarily disclose their COVID status and willingly participates in the study.
Exclusion Criteria
- •1\.Employees who donâ??t want to participate in the study voluntarily.
- •2\.Employees who cannot read and write English.
- •3\.Out sourced employees of MAHE.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A prospective study to investigate the effect of CBM558 combined with pembrolizumab on gut microbiota and prognosis in patients with advanced urothelial carcinoma.JPRN-jRCTs031220689Taguchi Satoru30
Not yet recruiting
Not Applicable
To assess post Covid symptoms in patient admitted in Covid care centre at NISHealth Condition 1: B342- Coronavirus infection, unspecifiedCTRI/2022/02/040032ational Institute of Siddha
Recruiting
Not Applicable
Observational Study of the Effect of Cardiac Rehabilitaion on QOL in Patients with AMIJPRN-jRCT1050230042Kondo Takumi200
Active, not recruiting
Not Applicable
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-005710-11-DEOXXON Pharma AG75
Active, not recruiting
Not Applicable
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-005710-11-CZOXXON Pharma AG75